skip to content

eLesor Investments version="1.1" id="Layer_1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" x="0px" y="0px" viewBox="0 0 697.5 99.8" style="enable-background:new 0 0 697.5 99.8;" xml:space="preserve" aria-labelledby="title--mwlogoHeader desc--mwlogoHeader" role="img"> eLesor Site Logo A link that brings you back to the homepage.

Ocular Therapeutix Shares Up, Company Offers Preliminary 2Q Net Product Revenue

By Stephen Nakrosis

Shares of biopharmaceutical company Ocular Therapeutix, Inc. are trading higher in the after-hours market on Thursday following the company's release of preliminary second-quarter net product revenue.

The company said it was expecting total net product revenue of about $11.7 million for the second quarter, a better than 600% year-over-year increase.

The company also said net product revenue of Dextenza for the quarter ended June 30 is estimated at $11.1 million, and net product revenue of ReSure Sealant for the quarter estimated at $600,000.

At 5:47 p.m. EDT, the company's shares were trading 5.61% higher at $12.80. Volume at the time topped 70,000 shares.

The company's stock finished the day's regular-trading session with a 4.42% loss at $12.12 a share.

Ocular Therapeutix said it is focused on therapies for diseases and conditions of the eye using its "proprietary bioresorbable hydrogel-based formulation technology."

Write to Stephen Nakrosis at [email protected]




      

Partner Center